Table 1 Baseline characteristics of the PACE study cohort (2009–2012)
Characteristics Mean (SD) or % or Median (IQR) | Normal QTc (N = 40) | Prolonged QTca (N = 202) | Overall (N = 242) |
|---|---|---|---|
Demographics | |||
 Age (years) | 54 (16) | 55 (13) | 55 (13) |
 Male | 16 (40%) | 117 (58%) | 133 (55%) |
 African American | 29 (73) | 146 (72%) | 175 (72%) |
 PHQ-9 Total Depression Score | 4 (1, 7) | 4 (1, 8) | 4 (1, 8) |
ECG Metrics | |||
 QT Interval (ms) | 415.0 (29.3) | 459.9 (48.0) | 452.5 (48.4) |
 QTc (ms) | 433.8 (19.5) | 498.9 (43.1) | 488.1 (46.9) |
 QRST Angle (degrees) | 7.2 (5.2) | 9.3 (4.4) | 9.0 (4.6) |
 Heart Rate (ms) | 92.2 (13.5) | 85.7 (13.4) | 86.8 (13.6) |
 Heart Rate Variance (ms2) | 350.9 (107.4, 1103.8) | 640.5 (202.7, 1840.5) | 380.3 (128.8, 1228.9) |
LVHc | 5 (12.8%) | 27 (14.8%) | 32 (14.5%) |
Cardiovascular Risk Factors | |||
 LVMId (g/m2) | 134.7 (52.6) | 140.5 (45.0) | 139.5 (46.3) |
 CRP (μg/mL) | 3.2 (1.6, 7.4) | 6.4 (2.6, 15.0) | 5.8 (2.4, 14.9) |
 Diabetes | 17 (43%) | 121 (60%) | 138 (57%) |
 RAASb | 17 (46%) | 81 (44%) | 98 (44%) |
 Beta Blockers | 21 (53%) | 131 (65%) | 152 (63%) |
 Alpha-Blocker, Calcium Channel Blocker, Vasodilator | 31 (84%) | 142 (77%) | 173 (78%) |
 Diuretic | 4 (11%) | 46 (23%) | 50 (23%) |
 Congestive Heart Failure | 15 (38%) | 82 (41%) | 97 (40%) |
 Charlson Comorbidity Index | 3 (2, 5) | 4 (3, 6) | 4 (3, 6) |
 Baseline Length of Hemodialysis Treatment | 215.5 (24.0) | 215.9 (19.7) | 215.9 (20.3) |
 Interdialytic Weight Gain | 1.8 (0.6) | 2.2 (0.9) | 2.1 (0.9) |
 Use of QT Prolonging Medicationse | 11 (28%) | 74 (37%) | 85 (35%) |
 Non-dialysis Seated Systolic Blood Pressure | 129.9 (20.7) | 137.6 (25.6) | 136.4 (25.0) |
 Non-dialysis Seated Diastolic Blood Pressure | 69.4 (14.0) | 74.6 (13.7) | 73.7 (13.8) |
Outcome | |||
 Recovery Time (min) | 10 (7.5, 30) | 30 (10, 120) | 20 (10, 60) |